Contraceptive guidance updated
Contemporary OB/GYN summarised key changes from the 2024 U.S. medical eligibility criteria for contraceptive use, highlighting revised recommendations around thromboembolic risk in pregnancy and the postpartum period. The update specifically notes elevated risk considerations for patients with conditions such as sickle cell disease that affect contraceptive eligibility and counselling. (contemporaryobgyn.net)
The Centers for Disease Control and Prevention’s 2024 contraceptive guidance rewrote parts of the safety chart doctors use, with new limits tied to blood-clot risk after pregnancy and in sickle cell disease. (cdc.gov) The update was published in the Morbidity and Mortality Weekly Report on August 8, 2024, replacing the 2016 U.S. Medical Eligibility Criteria for Contraceptive Use after a January 25 to 27, 2023, expert meeting in Atlanta. The document covers who can safely use specific methods when medical conditions change the balance of risks and benefits. (cdc.gov) The system uses four categories: 1 means no restriction, 2 means benefits generally outweigh risks, 3 means risks usually outweigh benefits, and 4 means the method should not be used. The chart is meant for clinicians, not as one-size-fits-all advice for individual patients. (cdc.gov) One of the biggest revisions is postpartum use of combined hormonal contraception — the pill, patch, and ring that contain estrogen. For breastfeeding patients fewer than 21 days after delivery, the method remains category 4 because the risk of venous thromboembolism, a dangerous blood clot in a vein, is highest in that period. (cdc.gov) For breastfeeding patients 21 to fewer than 30 days postpartum, combined hormonal contraception is category 3 even without other clotting risks, and the Centers for Disease Control and Prevention says added factors such as age 35 or older, prior venous thromboembolism, thrombophilia, body mass index of at least 30, smoking, preeclampsia, postpartum hemorrhage, or cesarean delivery can raise that to category 4. (cdc.gov) The 2024 guidance also revised recommendations for sickle cell disease, a blood disorder that already raises the risk of stroke and clotting. Contemporary OB/GYN reported that the update moved depot medroxyprogesterone acetate, the birth-control shot, from category 1 to category 2 or 3 because of concerns about venous thrombosis, while hormonal IUDs and progestin-only pills remained favorable options. (contemporaryobgyn.net) The same update added a new section for chronic kidney disease and revised recommendations across deep venous thrombosis, pulmonary embolism, thrombophilia, lupus, cirrhosis, solid-organ transplantation, and drug interactions with antiretroviral medicines. It also folded in newer contraceptive products, including newer combined oral pills, patches, rings, levonorgestrel intrauterine devices, and a vaginal pH modulator. (cdc.gov) The guidance sits alongside a companion 2024 practice document that tells clinicians how to start, switch, and manage methods once a patient is medically eligible. The Centers for Disease Control and Prevention also released an updated contraception app and summary chart as quick-reference tools for offices and clinics. (cdc.gov; cdc.gov) The Contemporary OB/GYN article added another wrinkle in 2025: after publication, it said, the federal webpages were briefly removed and then restored with a disclaimer about gender-inclusive language. As of April 15, 2026, the Centers for Disease Control and Prevention pages and the 2024 guidance remain publicly available. (contemporaryobgyn.net; cdc.gov) For patients, the practical change is simple: the same contraceptive method can move from acceptable to inadvisable depending on how many days have passed since delivery, whether estrogen is involved, and whether a condition such as sickle cell disease adds clotting risk. The 2024 chart gives clinicians a more detailed map for those conversations. (cdc.gov; cdc.gov)
